


LSE Investor Presentation introducing Cytolytix



Disclaimer



The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the 'Presentation') have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ('FSMA'). Reliance upon the Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of the Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind.

The Presentation is being supplied to you solely for your information and does not propose to contain all information that may be required to evaluate Valirx PLC ("the Company"). The Presentation has been prepared by, and is the sole responsibility of, the Company. The directors of the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

The Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into, any contract. Any investment in shares in the Company should only be made by you on the basis of information relating to the Company published through a regulatory news service, and your own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice as you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information contained in the Presentation or on its completeness, accuracy or fairness, nor is any responsibility accepted for any errors or misstatements in, or omission from, the Presentation or any direct or consequential loss however arising from any use of, or reliance on, the Presentation or otherwise in connection with it.

The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Canada, Japan, Australia, the Republic of South Africa or the Republic of Ireland or to, or for the account or benefit of, any US persons or any national, citizen or resident of the US, Canada, Japan, Australia, the Republic of South Africa or the Republic of Ireland, unless such offer or sale would qualify for an exemption from registration under the US Securities Act and/or any other applicable securities laws.

This Presentation is for distribution in the UK only to persons who: (a) fall within the exemptions contained in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (including certain investment professionals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts and other persons as specified therein); and (b) are "qualified investors" (within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) (as the same forms part of English law) ("Prospectus Regulation"), acting as principal or in circumstances to which section 86(2) of the Financial Services and Markets Act 2000 ("FSMA") applies, and (c) any other persons who may lawfully receive it. In addition, this Presentation is directed only at persons having professional experience in matters relating to investments and any investment or investment activity to which this Presentation relates is only available to such persons; persons who do not have professional experience in matters relating to investments should not rely or act on this Presentation.

The Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects, developments and business strategies of the Company. Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in the Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Company's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of the Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

No undertaking, representation, warranty or other assurance, expressed or implied, is made or given by or on behalf of the Company or any of its directors, officers, partners, employees or advisers or any other person as to the accuracy or the completeness of the information or opinions contained herein and to the extent permitted by law no responsibility or liability is accepted by any of them for any such information or opinions. Notwithstanding the aforesaid, nothing in this disclaimer shall limit or exclude liability for fraud.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that you have read and agree to comply with the contents of this disclaimer.



£2.5m raised (June 22)
– significantly reduced
cash burn



2 therapies
undergoing out-
licensing



Focus on oncology
and women's health



Evaluation projects
pipeline



tCRO strategy



Cytolytix

Single asset
subsidiary for triple
negative breast
cancer

Team – a Deep Experience of the Sector

Core Strategy Team



Dr Suzanne Dilly
Chief Executive Officer

- Entrepreneur
- Pharmaceutical scientist
- Translational expertise



Mark Treharne
Corporate Development Manager

- Innovator network
- Investor Relations
- Business development



Dr Kevin Cox
Non-executive Chairman

- >25 years in Life Science leadership
- M&A; Scale-up
- Pharma Services



NEW!

Dr Cathy Tralau-Stewart
Chief Scientific Officer

- Pharmacologist with >25 years in Life Science leadership
- Academic, Start up, Biotech and Big Pharma
- Delivered multiple candidates and marketed drugs

Other Board Members:

Martin Lampshire (NED)
Gerry Desler (CFO)
Stella Panu (NED) **NEW!**


Science Advisory:

Wilson Wanderley (Statistics)
Christophe Chassagnole (Bioinformatics)
Mark Eccleston (Biologist pre-clinical)
Paul Taylor (synthesis, academia)


Commercial Advisory:

Jerry Randall (Strategy, AIM funding)
Andrew Carnegie (Pharma services)
Mark Eccleston (Pharma services)

Development Pipeline




ValiRx Provides Solid Start on Pathway to Sales



Getting the preclinical stage right can add billions to the value of drugs

Bridging the Gap Needs Rigorous Preclinical Work



Only c10% of academic drug development is commercialised...

CLX001 – a novel cancer cell buster

Cytolytix



Indication:

- Triple Negative Breast Cancer and other hard to treat cancers



Mode of Action:

- Creates pores in cancer cell membranes, causing lysis and cell death
- Highly specific to cancerous cells, without needing a specific cancer marker



Product:

- Synthetic peptide encapsulated in a proprietary nano-formulation for intravenous injection



Status:

- Promising *in vitro* and *in vivo* data from Kings College London and ValiRx
- Undergoing regulatory standard preclinical assessment to progress to clinical ready status
- Cytolytix set up as single asset subsidiary to facilitate out-licencing/sale



USP:

- Novel MoA indicates a high specificity towards cancer cells
- Independent of cancer cell surface markers, potential to treat TNBC and a wide range of other cancers

Triple Negative Breast Cancer (TNBC)

Cytolytix


- Characterised by lack of Estrogen Receptors (ER); Progesterone Receptors (PR) and HER2 Receptors – hence ‘triple negative’
- Breast cancer can be diagnosed as triple negative, or recur as triple negative on relapse after earlier chemotherapies
- Difficult to treat with targeted therapies due to lack of receptors – relies on traditional chemotherapy agents
- Poor clinical outcomes and high side effect levels
- Huge unmet medical need

CLX001 does not need cell surface receptors / markers to target cancer



Mechanism of Action

Cytolytix



Status of Development

Cytolytix

- *In vivo* assays by Kings showed **eradication** of tumours in some animals after a ten day treatment schedule, animals remained tumour-free at 200 days
- *In vitro* assays by ValiRx and Kings show activity in ovarian as well as breast cancer in patient derived cells
- Toxicology promising to date from ValiRx and Kings experiments
- Optimisation of nano-formulation planned for industrial-scale processing
- Dose schedule optimisation planned with scaled formulation
- Follow-on programmes possible with additional indications

Contacts

- Suzanne Dilly – Chief Executive Officer
 - Suzanne.Dilly@valirx.com
- Cathy Tralau-Stewart – Chief Scientific Officer
 - Cathy.Tralau-Stewart@valirx.com
- Kevin Cox – Non-Executive Chairman
 - Kevin.Cox@valirx.com
- Mark Treharne – Corporate Development Manager
 - Mark.Treharne@valirx.com

Valirx PLC (AIM:VAL)

Eliot Park Innovation Centre, 4 Barling Way, Nuneaton, CV10 7RH